Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

terminated125%
completed250%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

NCT03949153
completedphase_2

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

NCT03697564
terminatedphase_1

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

NCT04173325
withdrawnphase_2

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506

Clinical Trials (4)

Showing 4 of 4 trials
NCT03949153Phase 1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

Completed
NCT03697564Phase 2

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Completed
NCT04173325Phase 1

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Terminated
NCT04042506Phase 2

SBRT as a Vaccination for Metastatic Melanoma

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4